MUTANT P53 IN PATIENTS WITH INVASIVE CERVICAL-CANCER STAGES IB TO IIB

被引:27
作者
KAINZ, C [1 ]
KOHLBERGER, P [1 ]
GITSCH, G [1 ]
SLIUTZ, G [1 ]
BREITENECKER, G [1 ]
REINTHALLER, A [1 ]
机构
[1] UNIV VIENNA,INST PATHOL,GYNECOPATHOL UNIT,VIENNA,AUSTRIA
关键词
D O I
10.1006/gyno.1995.1127
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study evaluates the prognostic value of mutant p53 protein overexpression in 109 surgically treated cervical cancer stages IB to IIB. Squamous cell carcinoma stages IB, IIA, and IIB were present in 52, 13, and 44 cases, respectively. We performed immunohistochemistry using a monoclonal antibody against the p53 suppressor gene product (clone BP53-12). Data were analyzed for the end points of disease-free survival and overall survival. In 109 tissue specimens we detected 22 cases of p53 expression. Six of 22 patients with p53 expression and 21 of 87 patients without p53 expression showed tumor recurrences. p53 expression showed no significant correlation to age, tumor stage or lymph node involvement. In the univariate analysis p53 expression showed no prognostic value for disease-free (P = 0.5) and overall survival (P = 0.6). Multivariate analysis showed a significant prognostic value for established prognostic parameters while p53 expression had no prognostic value for recurrence-free (P = 0.6) and overall survival (P = 0.5). In contrast to other malignancies mutant p53 overexpression showed no relation to prognosis in surgically treated cervical cancer stage IB to IIB. (C) 1995 Academic Press, Inc.
引用
收藏
页码:212 / 214
页数:3
相关论文
共 15 条
[1]   ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
ELLEDGE, R ;
FUQUA, SAW ;
BROWN, RW ;
CHAMNESS, GC ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :200-206
[2]   PROGNOSTIC FACTORS AND OPERATIVE TREATMENT OF STAGE-IB TO STAGE-IIB CERVICAL-CANCER [J].
BURGHARDT, E ;
PICKEL, H ;
HAAS, J ;
LAHOUSEN, M .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1987, 156 (04) :988-996
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   ACTIVATING MUTATIONS FOR TRANSFORMATION BY P53 PRODUCE A GENE-PRODUCT THAT FORMS AN HSC70-P53 COMPLEX WITH AN ALTERED HALF-LIFE [J].
FINLAY, CA ;
HINDS, PW ;
TAN, TH ;
ELIYAHU, D ;
OREN, M ;
LEVINE, AJ .
MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (02) :531-539
[5]  
GITSCH G, 1992, ANTICANCER RES, V12, P2241
[6]   IMMUNOHISTOCHEMISTRY IN PELVIC NODES OF PATIENTS WITH CERVICAL-CANCER [J].
GITSCH, G ;
REINTHALLER, A ;
KOHLBERGER, P ;
TATRA, G ;
BREITENECKER, G .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1992, 99 (03) :265-267
[7]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[8]   P53 OVEREXPRESSION IN FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE DETECTED BY IMMUNOHISTOCHEMISTRY [J].
KERNS, BJM ;
JORDAN, PA ;
MOORE, MBH ;
HUMPHREY, PA ;
BERCHUCK, A ;
KOHLER, MF ;
BAST, RC ;
IGLEHART, JD ;
MARKS, JR .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1992, 40 (07) :1047-1051
[9]   P53 MUTATIONS INCREASE RESISTANCE TO IONIZING-RADIATION [J].
LEE, JM ;
BERNSTEIN, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (12) :5742-5746
[10]   THE P53 TUMOR SUPPRESSOR GENE [J].
LEVINE, AJ ;
MOMAND, J ;
FINLAY, CA .
NATURE, 1991, 351 (6326) :453-456